ENGLetrozole Drug Description
Letrozole is a medication primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It belongs to a class of drugs known as aromatase inhibitors, which work by reducing estrogen levels in the body. Lowering estrogen can help slow or reverse the growth of certain types of breast tumors that require estrogen to grow.
Mechanism of Action
The primary action of letrozole involves the inhibition of aromatase, an enzyme responsible for converting androgens into estrogens. This process is particularly critical after menopause when most estrogen is produced through this conversion rather than the ovaries. By blocking aromatase, letrozole effectively decreases the amount of circulating estrogen, leading to reduced stimulation of estrogen-sensitive tumors.
Indications
Letrozole is indicated for:
- Treatment of early-stage breast cancer in postmenopausal women following surgery and radiation therapy.
- Adjuvant therapy for hormone receptor-positive breast cancer.
- Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following anti-estrogen therapy.
Dosage and Administration
The standard dosage of letrozole is typically 2.5 mg taken orally once daily. Treatment duration may vary based on clinical response and physician recommendations. Patients should follow their healthcare provider’s instructions regarding administration and adherence to the prescribed regimen.
Side Effects
- Hot flashes
- Joint pain or stiffness
- Fatigue
- Nausea
- Increased risk of osteoporosis and fractures
Patients experiencing severe or Letrozol SUN 2,5 mg drug description persistent side effects should contact their healthcare provider for guidance.
Contraindications and Precautions
Letrozole is contraindicated in:
- Pregnant or breastfeeding women.
- Individuals with hypersensitivity to letrozole or any of its components.
Caution is advised in patients with liver impairment, as adjustments to the dosage may be required. Regular monitoring and evaluations are recommended to ensure patient safety throughout the treatment period.
Conclusion
In summary, letrozole is a vital therapeutic option for managing breast cancer in postmenopausal women. Its role as an aromatase inhibitor allows it to effectively lower estrogen levels, thereby supporting the treatment of estrogen-dependent tumors. As with any medication, thorough discussions with healthcare professionals regarding risks, benefits, and individual patient circumstances are essential for optimal outcomes.
